Progression-free survival as a surrogate for overall survival in advanced/recurrent gastric cancer trials: a meta-analysis
about
Therapeutic effect of apatinib on overall survival is mediated by prolonged progression-free survival in advanced gastric cancer patients.Progression-free survival as a surrogate endpoint for overall survival in patients with third-line or later-line chemotherapy for advanced gastric cancer.Multitrial Evaluation of Progression-Free Survival as a Surrogate End Point for Overall Survival in First-Line Extensive-Stage Small-Cell Lung Cancer.Surrogate End Points for Overall Survival in Loco-Regionally Advanced Nasopharyngeal Carcinoma: An Individual Patient Data Meta-analysis.Early Relapse of Follicular Lymphoma After Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Defines Patients at High Risk for Death: An Analysis From the National LymphoCare Study.Surrogate markers of overall survival in metastatic colorectal cancer: an evolving challenge still more complex with repeat surgery.Microarray analysis in gastric cancer: a review.Endpoints and cutpoints in head and neck oncology trials: methodical background, challenges, current practice and perspectives.Chemotherapy for advanced gastric cancer.A Poisson approach to the validation of failure time surrogate endpoints in individual patient data meta-analyses.Evolving treatments for advanced gastric cancer: appraisal of the survival trend.Progression-Free Survival as a Surrogate for Overall Survival in Clinical Trials of Targeted Therapy in Advanced Solid Tumors.Anti-angiogenic Therapy in Patients with Advanced Gastric and Gastroesophageal Junction Cancer: A Systematic Review.Impact of progression type on overall survival in patients with advanced gastric cancer based on randomized phase III study of S-1 plus oxaliplatin versus S-1 plus cisplatin.Progression-free survival as surrogate end point for overall survival in clinical trials of HER2-targeted agents in HER2-positive metastatic breast cancer.Correlations of survival with progression-free survival, response rate, and disease control rate in advanced biliary tract cancer: a meta-analysis of randomised trials of first-line chemotherapy.Sample size determination for the current strategy in oncology Phase 3 trials that tests progression-free survival and overall survival in a two-stage design framework.Acceptance of surrogate end points in clinical trials supporting approval of drugs for cancer treatment by the Japanese regulatory agency.Depth of response predicts the clinical outcome of advanced HER2-positive gastric cancer to trastuzumab-based first-line chemotherapy.A systematic assessment of Cochrane reviews and systematic reviews published in high-impact medical journals related to cancer.Overall survival and post-progression survival are potent endpoint in phase III trials of second/third-line chemotherapy for advanced or recurrent epithelial ovarian cancer.Lapatinib-associated mucocutaneous toxicities are clinical predictors of improved progression-free survival in patients with human epidermal growth factor receptor (HER2)-positive advanced breast cancer.
P2860
Q33710118-09D42CF4-27E7-41E1-A5E8-B435B07CECA9Q35541950-67ADC2FD-2745-47FA-87B8-1B668B408BCEQ35825822-283F9820-E13E-4C8E-9A68-E517CA95CCEEQ36215439-BD748477-999C-40EA-84D7-EB553893B5B4Q36934350-04B4345D-AF1E-4537-9234-4CD460F89D33Q37402280-3B4C44D2-ED01-4BF4-8F22-9032D9C718ACQ38251498-3E352B85-228D-4246-B55A-96CBE52BAD7CQ38312486-AFD6F68B-CA3A-4E83-9CA8-DB97552FD194Q38604012-C57982C3-0EAA-434C-806A-758FFCAAF8F8Q38691539-C9FF66F5-7D4C-44B0-AFC5-51D8BC236E7CQ38823374-B9849B64-3B09-4446-AA6B-7DBFFF1A77B0Q38880510-931BA50B-5395-4524-974C-8F352F3E594FQ39067386-C04FD4B2-3753-4DA5-A0B9-1B100347D427Q39206214-9F7F2430-C607-41F9-A45E-CB297172E1EAQ39933767-6008F159-8B38-42F3-86CD-6AF1B6C27AE3Q40824695-88104936-A7D5-4212-B297-9BB4BD28DA2AQ47189344-82543750-3441-4C5F-BFC6-84A20C6253CCQ47591645-4CC3FFCC-9538-418A-9F28-2BF556369400Q47932548-D3A098ED-4A55-4625-8C89-2DE3342E51E9Q53834783-F9CD8619-71BD-4823-B116-913FFB64123DQ54951150-C762FDFC-044D-40B8-A5B8-356F0C003943Q55070923-82FE8B8A-910A-4DDF-AC1B-D4934D89508B
P2860
Progression-free survival as a surrogate for overall survival in advanced/recurrent gastric cancer trials: a meta-analysis
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 09 October 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Progression-free survival as a ...... cancer trials: a meta-analysis
@en
Progression-free survival as a ...... ancer trials: a meta-analysis.
@nl
type
label
Progression-free survival as a ...... cancer trials: a meta-analysis
@en
Progression-free survival as a ...... ancer trials: a meta-analysis.
@nl
prefLabel
Progression-free survival as a ...... cancer trials: a meta-analysis
@en
Progression-free survival as a ...... ancer trials: a meta-analysis.
@nl
P2093
P2860
P50
P356
P1476
Progression-free survival as a ...... cancer trials: a meta-analysis
@en
P2093
Arnaud Roth
Atsushi Ohtsu
Eric Van Cutsem
GASTRIC group
Harry Bleiberg
Junichi Sakamoto
Kohei Shitara
Markus Moehler
Mitsuru Sasako
Narikazu Boku
P2860
P304
P356
10.1093/JNCI/DJT269
P407
P577
2013-10-09T00:00:00Z